Ignite Creation Date:
2024-05-06 @ 6:03 PM
Last Modification Date:
2024-10-26 @ 2:40 PM
Study NCT ID:
NCT05528055
Status:
RECRUITING
Last Update Posted:
2022-09-06
First Post:
2022-05-10
Brief Title:
A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
Sponsor:
Jiangsu Simcere Pharmaceutical Co Ltd
Organization:
Jiangsu Simcere Pharmaceutical Co Ltd
Study Overview
Official Title:
A Phase I Study to Investigate the Safety Tolerability Preliminary Efficacy and PharmacokineticsPK of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
Status:
RECRUITING
Status Verified Date:
2022-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase 1 open label multi center dose escalation and expansion study will assess the safety tolerability PK and preliminary efficacy of SCR-6920 capsule in participants with advanced malignant tumors The purpose of the study is to identify the maximum tolerated dose MTD andor the recommended Phase 2 dose RP2D and to confirm the tolerability and preliminary efficacy of SCR-6920 in participants with advanced solid tumors and relapsedrefractory non-Hodgkin lymphomaNHL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None